However, the pleiotropic and context-dependent roles of TGF-β in tissue homeostasis and early tumor suppression, together with the lack of approved TGF-β–targeted agents and concerns about systemic toxicity, currently constrain the immediate clinical deployment of direct TGF-β inhibition in OC. Here, TGFB1 is linked to neoplasm.